Logo Logo

Category Archives: "Partners"

  1. Home
  2. INforMS
  3. Page 7
Mar 29, 2019
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
INforMS, Partners
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
Elizabeth Porco
Read More
...123
0
Mar 27, 2019
Novartis receives FDA approval for MAYZENT (Siponimod)
INforMS, Partners
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
Elizabeth Porco
Read More
...143
0
Oct 11, 2018
TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS
INforMS, Partners
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]
Elizabeth Porco
Read More
...141
0
Oct 10, 2018
Novartis announces FDA filing acceptance of Siponimod (BAF312)
INforMS, Partners
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating [...]
Elizabeth Porco
Read More
...154
0
Oct 10, 2018
New efficacy and safety data on multiple sclerosis portfolio to be presented
INforMS, Partners
​Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show [...]
Elizabeth Porco
Read More
...192
0
Oct 10, 2018
Press release – Ocrevus data show early initiation reduces progression
INforMS, Partners
Dear Advocates, OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in [...]
Elizabeth Porco
Read More
...141
0
Sep 12, 2018
Novartis announces PARADIGMS study demonstrating benefit of Gilenya®
INforMS, Partners
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents [...]
Elizabeth Porco
Read More
...145
0
Aug 13, 2018
Call for test sites: using patient-reported outcomes to drive multiple sclerosis care
Partners
Researchers at Northwestern University are seeking volunteers to participate in the pilot testing of a new quality measure for [...]
Elizabeth Porco
Read More
...105
0
Jun 14, 2018
Genentech announces new Ocrevus (Ocrelizumab) data for PPMS
INforMS, Partners
Dear Advocates, We are pleased to announce that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European [...]
Elizabeth Porco
Read More
...128
0
May 01, 2018
TREAT-MS
CMSC PR, Partners
Dr. Scott Newsome and Dr. Ellen Mowry are pleased to announce the launch of their TREAT-MS trial at Hopkins. They will be activating and [...]
Elizabeth Porco
Read More
...112
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM